From Nick Cafardo’s Sunday notes column in the Boston Globe:
Jeff Samardzija, RHP, Cubs — Trade talks have been going on and when push comes to shove, he might get traded. But the Cubs’ No. 1 preference would be to re-sign Samardzija and lock him in beyond 2015 and build their future around him, according to a major league source. The Cubs will continue to work on both fronts until the culmination of a long-term extension has been reached or if the extension is improbable.
The Blue Jays have been linked recently to Samardzija and many other teams have undoubtedly checked in. The 28-year-old had a disappointing 4.34 ERA and 1.35 WHIP in 33 starts this summer for the Cubs, but he struck out 214 batters in 213 2/3 innings. Everybody loves a power pitcher.
Samardzija is arbitration-eligible for the second time this winter. He made $2.64 million in 2013.
Michael Fulmer was the 2016 AL Rookie of the Year Award winner. Last year he had his worst season as a major leaguer, finishing 3-12 with a 4.69 ERA and a 110/46 K/BB ratio in 132 1/3 innings. This spring he has been utterly lost in eight innings of work, getting hit hard and exhibiting diminished velocity. A few days ago, the Tigers shut him down and said they’d work on his mechanics.
Now comes the news that no one wanted to hear: the Tigers have announced that Dr. James Andrews has recommended that he get Tommy John surgery.
Fulmer is said to be seeking a third opinion — before Andrews he had an MRI and team doctors feared the worst — but let’s be real about what’s gonna happen here: Fulmer is going to miss the entire 2019 season and, in all likelihood, a good chunk of 2020 as well.
Tough break for Fulmer, one of the few good pitchers the Tigers had developed in some time.